SCHEMBL7019079

SCHEMBL7019079

Cc1ccc(C(CO)c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.49
CNR2 P34972 2/20 0.49
LMNA P02545 3/20 0.47
TRPA1 O75762 3/20 0.45
CACNA2D1 P54289 1/20 0.44
CACNA1B Q00975 1/20 0.44
CACNB1 Q02641 1/20 0.44
CACNA1C Q13936 1/20 0.44
CASR P41180 1/20 0.44
CYP19A1 P11511 1/20 0.44
TSHR P16473 1/20 0.43
ALOX12 P18054 1/20 0.43
ACHE P22303 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.42
HTR2A P28223 2/20 0.41
HRH1 P35367 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193835 0.85 HTR2A (0.52) LMNATRPA1TSHRHTR2AHRH1
Hydrochloric Acid SCHEMBL6251948 0.83 HTR2A (0.50) LMNATRPA1TSHRHTR2AHRH1
Ammonia Solution, Strong SCHEMBL28352255 0.83 HTR2A (0.50) LMNATRPA1TSHRHTR2AHRH1
SCHEMBL27468204 0.83 CNR1 (0.54) CNR1CNR2LMNATRPA1CACNA2D1
SCHEMBL10042121 0.82 ALDH1A1 (0.47) CNR1CNR2LMNACACNA2D1CACNA1B
Dimethylamine SCHEMBL10622831 0.81 HTR2A (0.52) LMNATRPA1CASRTSHRALOX12
SCHEMBL29723649 0.81 CNR1 (0.56) CNR1CNR2LMNACASRCYP19A1
SCHEMBL11359363 0.79 CHRNB2 (0.61) LMNATRPA1CASRKMT2AALDH1A1
Acetic Acid SCHEMBL28538311 0.79 MTNR1A (0.52) LMNATRPA1KMT2AHTR2AHRH1
SCHEMBL2356591 0.79 HTR2A (0.48) CNR1CNR2LMNACACNA2D1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9387254-B2 Prodrugs and drug-macromolecule conjugates having controlled drug release rates PROLYNX LLC (US) 2016-07-12 US disclosed
US-20140296476-A1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES PROLYNX LLC 2014-10-02 US disclosed
US-8680315-B2 Prodrugs and drug-macromolecule conjugates having controlled drug release rates PROLYNX, LLC (US) 2014-03-25 US disclosed
EP-0901491-B1 TROPANE DERIVATIVES USEABLE IN PARTICULAR FOR IN VIVO DETECTION OF DOPAMINE TRANSPORTERS SCHERING AG (DE) 2003-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296476-A1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES ABCB1, ABCB11, DNPEP CNR1 584/4885CNR2 1310/4885LMNA 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.